Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18f]olaparib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
`[18f]olaparib` is an investigational radiopharmaceutical PET tracer developed by the Universitair Medisch Centrum Groningen (UMCG) for the non-invasive assessment of Poly (ADP-ribose) polymerase (PARP) expression in tumors. As a fluorine-18 labeled analog of the clinical PARP inhibitor olaparib, it retains high binding affinity for PARP1 and PARP2 enzymes. These enzymes are critical for DNA damage repair and are frequently overexpressed in various cancers, including head and neck squamous cell carcinoma (HNSCC). By utilizing Positron Emission Tomography (PET) imaging, `[18f]olaparib` enables the quantification of PARP density in vivo, which may serve as a predictive biomarker for identifying patients likely to respond to PARP inhibitor therapy and for monitoring therapeutic efficacy or target engagement.
- Other names
- Fluorine-18 olaparibFluorine18 olaparibFluorine 18 olaparib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PARP3 (Poly(adp-ribose) polymerase 3)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on [18f]olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18f]olaparib.